NCT03258567 2026-03-06
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT04554914 2026-02-20
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Recruiting
NCT07368153 2026-01-26
IDEP
University Hospital, Basel, Switzerland
Phase 2 Not yet recruiting
NCT07261215 2025-12-03
Zuberitamab for EBV Infection Post-Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT04925544 2025-10-21
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
Phase 2 Active not recruiting
NCT07138989 2025-08-24
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT03266653 2025-08-08
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
New York Medical College
Phase 2 Recruiting
NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed